In December 2014, Janssen entered into a collaboration agreement with us to develop and commercialize MGD011 (CD19 x CD3). Learn more
In May 2016, Janssen entered into a collaboration agreement with us to develop and commercialize MGD015, a DART molecule designed to eliminate cells that overexpress an undisclosed antigen in various hematological malignancies and solid tumors. Learn more
In both collaborations with Janssen, MacroGenics retains co-promotion rights in the U.S. and may elect to fund a portion of late-stage clinical development to receive a profit share in the U.S. and Canada in lieu of royalties in these territories.